NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.59 -0.03 (-4.84 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$0.59
Today's Range$0.56 - $0.62
52-Week Range$0.29 - $2.02
Volume694,825 shs
Average Volume754,134 shs
Market Capitalization$25.70 million
P/E Ratio-0.58
Dividend YieldN/A
Beta3.52

About Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals logoEyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds/defects and epitheliopathies, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and anterior uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body, as well as Eyegate II drug delivery system. The company has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.

Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EYEG
CUSIPN/A
Phone781-788-8869

Debt

Debt-to-Equity RatioN/A
Current Ratio1.18
Quick Ratio1.18

Price-To-Earnings

Trailing P/E Ratio-0.58
Forward P/E Ratio-0.98
P/E GrowthN/A

Sales & Book Value

Annual Sales$410,000.00
Price / Sales60.06
Cash FlowN/A
Price / CashN/A
Book Value$0.13 per share
Price / Book4.54

Profitability

EPS (Most Recent Fiscal Year)($1.02)
Net Income$-13,210,000.00
Net Margins-2,480.28%
Return on Equity-653.57%
Return on Assets-93.74%

Miscellaneous

Employees17
Outstanding Shares41,740,000

Eyegate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

What is Eyegate Pharmaceuticals' stock symbol?

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

How were Eyegate Pharmaceuticals' earnings last quarter?

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) posted its earnings results on Friday, March, 2nd. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.04. Eyegate Pharmaceuticals had a negative return on equity of 653.57% and a negative net margin of 2,480.28%. View Eyegate Pharmaceuticals' Earnings History.

What price target have analysts set for EYEG?

1 brokerages have issued 1-year target prices for Eyegate Pharmaceuticals' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Eyegate Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Eyegate Pharmaceuticals.

Are investors shorting Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals saw a decline in short interest in the month of April. As of April 30th, there was short interest totalling 980,874 shares, a decline of 40.5% from the April 13th total of 1,647,564 shares. Based on an average daily volume of 2,785,591 shares, the short-interest ratio is presently 0.4 days. Approximately 3.6% of the shares of the stock are sold short.

Who are some of Eyegate Pharmaceuticals' key competitors?

Who are Eyegate Pharmaceuticals' key executives?

Eyegate Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen From, Chief Exec. Officer, Pres and Director (Age 55)
  • Dr. Barbara M. Wirostko M.D., Chief Medical Officer (Age 52)
  • Mr. Michael P. Manzo, VP of Engineering (Age 59)
  • Ms. Sarah Romano, Chief Financial Officer
  • Mr. Paul Perkins, Sr. Director of Fin. & HR and Director of Fin.

When did Eyegate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

Has Eyegate Pharmaceuticals been receiving favorable news coverage?

Press coverage about EYEG stock has trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eyegate Pharmaceuticals earned a daily sentiment score of 0.16 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 45.66 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Eyegate Pharmaceuticals' major shareholders?

Eyegate Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include ARMISTICE CAPITAL, LLC (40.20%), ARMISTICE CAPITAL, LLC (50.80%) and ARMISTICE CAPITAL, LLC (4.99%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano, Stephen From and Ventech Capital Ii. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

How do I buy shares of Eyegate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eyegate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $0.59.

How big of a company is Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals has a market capitalization of $25.70 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.

How can I contact Eyegate Pharmaceuticals?

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.


MarketBeat Community Rating for Eyegate Pharmaceuticals (EYEG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Eyegate Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYEG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eyegate Pharmaceuticals (NASDAQ:EYEG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Eyegate Pharmaceuticals in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 408.47%. The high price target for EYEG is $3.00 and the low price target for EYEG is $3.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.00$3.00$3.00$7.00
Price Target Upside: 408.47% upside417.24% upside400.00% upside554.21% upside

Eyegate Pharmaceuticals (NASDAQ:EYEG) Consensus Price Target History

Price Target History for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals (NASDAQ:EYEG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018HC WainwrightSet Price TargetBuy$3.00MediumView Rating Details
5/19/2017Noble FinancialReiterated RatingBuyLowView Rating Details
12/6/2016Chardan CapitalReiterated RatingBuy$6.00N/AView Rating Details
12/1/2016Rodman & RenshawReiterated RatingBuy$10.00N/AView Rating Details
6/28/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Eyegate Pharmaceuticals (NASDAQ:EYEG) Earnings History and Estimates Chart

Earnings by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals (NASDAQ:EYEG) Earnings Estimates

2018 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.21)($0.21)($0.21)
Q3 20181($0.15)($0.15)($0.15)
Q4 20181($0.12)($0.12)($0.12)

Eyegate Pharmaceuticals (NASDAQ EYEG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2018Q1($0.24)($0.14)$0.49 million$1.10 millionViewN/AView Earnings Details
3/2/2018Q4 2017($0.25)($0.21)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.24)($0.24)$0.16 million$0.08 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.19)($0.28)$1.52 million$0.15 millionViewN/AView Earnings Details
5/8/20173/31/2017($0.39)($0.39)$0.22 million$0.19 millionViewN/AView Earnings Details
2/23/2017Q4 2016($0.44)($0.38)$0.20 million$0.16 millionViewN/AView Earnings Details
11/1/2016Q3 2016($0.46)($0.36)$0.20 million$0.27 millionViewN/AView Earnings Details
8/10/2016Q2 2016($0.31)($0.46)$0.24 millionViewN/AView Earnings Details
5/13/2016Q1 2016($0.25)($0.31)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.20)($0.24)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.19)ViewN/AView Earnings Details
8/12/2015Q2 2015($0.24)ViewN/AView Earnings Details
5/15/2015Q1 2015($3.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Eyegate Pharmaceuticals (NASDAQ:EYEG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Eyegate Pharmaceuticals (NASDAQ EYEG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.60%
Institutional Ownership Percentage: 3.03%
Insider Trading History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Institutional Ownership by Quarter for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Eyegate Pharmaceuticals (NASDAQ EYEG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Armistice Capital Master FundDirectorBuy1,725$0.56$966.00View SEC Filing  
5/14/2018Armistice Capital Master FundDirectorBuy15,758$0.53$8,351.74View SEC Filing  
5/11/2018Armistice Capital Master FundMajor ShareholderBuy177,012$0.51$90,276.12View SEC Filing  
5/8/2018Armistice Capital Master FundMajor ShareholderBuy137,230$0.46$63,125.80View SEC Filing  
4/26/2018Armistice Capital Master FundMajor ShareholderBuy165,522$0.54$89,381.88View SEC Filing  
4/20/2018Armistice Capital Master FundMajor ShareholderBuy2,534,478$0.49$1,241,894.22View SEC Filing  
4/17/2018Armistice Capital Master FundMajor ShareholderBuy10,479,970$0.36$3,772,789.20View SEC Filing  
8/15/2017Sarah RomanoCFOBuy10,000$1.00$10,000.0032,500View SEC Filing  
8/10/2017Stephen FromInsiderBuy12,500$1.03$12,875.00272,465View SEC Filing  
3/6/2017Morton GoldbergDirectorSell8,919$3.00$26,757.009,441View SEC Filing  
9/15/2016Stephen FromInsiderBuy15,000$1.49$22,350.00139,965View SEC Filing  
6/15/2016Morton GoldbergDirectorSell15,000$3.16$47,400.0017,277View SEC Filing  
6/10/2016Ventech Capital IiMajor ShareholderSell28,600$3.04$86,944.001,608,973View SEC Filing  
6/8/2016Ventech Capital IiMajor ShareholderSell29,400$3.25$95,550.001,641,540View SEC Filing  
6/7/2016Morton GoldbergDirectorSell10,939$3.31$36,208.0943,216View SEC Filing  
2/19/2015(Innoven Partenaires S.A. IpsaMajor ShareholderBuy366,667$6.00$2,200,002.00View SEC Filing  
2/19/2015Paul G ChaneyDirectorBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eyegate Pharmaceuticals (NASDAQ EYEG) News Headlines

Source:
DateHeadline
Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Here’s How It Performed LatelyWant To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Here’s How It Performed Lately
finance.yahoo.com - May 26 at 8:13 AM
Eyegate Pharmaceuticals (EYEG) "Buy" Rating Reiterated at HC WainwrightEyegate Pharmaceuticals' (EYEG) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - May 23 at 1:01 PM
EyeGate advancing toward OBG INDEyeGate advancing toward OBG IND
seekingalpha.com - May 23 at 8:18 AM
BRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage GelBRIEF-EyeGate Submits Investigational Device Exemption Amendment For Ocular Bandage Gel
www.reuters.com - May 22 at 5:09 PM
EyeGate Addresses Majority of FDAs Action Items with Submission of Investigational Device Exemption Amendment ...EyeGate Addresses Majority of FDA's Action Items with Submission of Investigational Device Exemption Amendment ...
globenewswire.com - May 22 at 5:09 PM
Eyegate Pharma (EYEG) Responds to FDA Review, Addressing 3 of 4 Action Items in Second Amendment with ...Eyegate Pharma (EYEG) Responds to FDA Review, Addressing 3 of 4 Action Items in Second Amendment with ...
www.streetinsider.com - May 22 at 5:09 PM
EyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage GelEyeGate Addresses Majority of FDA’s Action Items with Submission of Investigational Device Exemption Amendment for Ocular Bandage Gel
finance.yahoo.com - May 22 at 5:09 PM
Reader Inquiry: Time To Buy EyeGate Pharmaceuticals?Reader Inquiry: Time To Buy EyeGate Pharmaceuticals?
seekingalpha.com - May 18 at 8:40 AM
BRIEF-EyeGate Pharmaceuticals Says On May 15, Board Increased Size To Eight From SevenBRIEF-EyeGate Pharmaceuticals Says On May 15, Board Increased Size To Eight From Seven
www.reuters.com - May 16 at 5:42 PM
EyeGate Pharmaceuticals Announces New Board Member, Steven BoydEyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
finance.yahoo.com - May 16 at 5:42 PM
EyeGate Pharma (EYEG) Given a $3.00 Price Target at HC WainwrightEyeGate Pharma (EYEG) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 14 at 12:42 PM
EyeGate Pharma (EYEG) Short Interest Down 40.5% in AprilEyeGate Pharma (EYEG) Short Interest Down 40.5% in April
www.americanbankingnews.com - May 14 at 1:10 AM
EyeGate Pharma (EYEG) Posts  Earnings Results, Beats Estimates By $0.10 EPSEyeGate Pharma (EYEG) Posts Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - May 12 at 11:17 AM
Armistice Capital Master Fund Acquires 177,012 Shares of EyeGate Pharma (EYEG) StockArmistice Capital Master Fund Acquires 177,012 Shares of EyeGate Pharma (EYEG) Stock
www.americanbankingnews.com - May 11 at 8:23 PM
Eyegate up 6% on Q1 resultEyegate up 6% on Q1 result
seekingalpha.com - May 11 at 5:58 PM
EyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business UpdateEyeGate Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 5:58 PM
EyeGate Pharma (EYEG) Major Shareholder Buys $63,125.80 in StockEyeGate Pharma (EYEG) Major Shareholder Buys $63,125.80 in Stock
www.americanbankingnews.com - May 8 at 10:28 PM
Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?
finance.yahoo.com - May 7 at 8:20 AM
EyeGate Pharma (EYEG) Upgraded to "Hold" at ValuEngineEyeGate Pharma (EYEG) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - May 4 at 12:13 AM
EyeGate Pharma (EYEG) to Release Earnings on MondayEyeGate Pharma (EYEG) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 8:16 AM
EyeGate Pharma (EYEG) Short Interest Up 216.7% in AprilEyeGate Pharma (EYEG) Short Interest Up 216.7% in April
www.americanbankingnews.com - April 28 at 2:54 AM
EyeGate Pharma (EYEG) Major Shareholder Purchases $89,381.88 in StockEyeGate Pharma (EYEG) Major Shareholder Purchases $89,381.88 in Stock
www.americanbankingnews.com - April 27 at 10:10 PM
EyeGate Announces $11.25 Million Public OfferingEyeGate Announces $11.25 Million Public Offering
finance.yahoo.com - April 25 at 5:29 PM
EyeGate Announces Completion of $11.25 Million Public OfferingEyeGate Announces Completion of $11.25 Million Public Offering
finance.yahoo.com - April 25 at 5:29 PM
Insider Buying: EyeGate Pharma (EYEG) Major Shareholder Purchases 2,534,478 Shares of StockInsider Buying: EyeGate Pharma (EYEG) Major Shareholder Purchases 2,534,478 Shares of Stock
www.americanbankingnews.com - April 20 at 7:22 PM
Form 4 EYEGATE PHARMACEUTICALS For: Apr 17 Filed by: FROM STEPHENForm 4 EYEGATE PHARMACEUTICALS For: Apr 17 Filed by: FROM STEPHEN
www.streetinsider.com - April 20 at 8:24 AM
EyeGate Pharma (EYEG) Major Shareholder Armistice Capital Master Fund Buys 10,479,970 SharesEyeGate Pharma (EYEG) Major Shareholder Armistice Capital Master Fund Buys 10,479,970 Shares
www.americanbankingnews.com - April 18 at 10:21 AM
Your Daily Pharma Scoop: Intercepts OCA, MediciNova In NASH, Pulse Biosciences DataYour Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data
seekingalpha.com - April 16 at 8:16 AM
EyeGate Pharma (EYEG) Given a $6.00 Price Target by HC Wainwright AnalystsEyeGate Pharma (EYEG) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 14 at 10:05 AM
Mid-Afternoon Market Update: Skyline Rises After Q3 Results; EyeGate Pharmaceuticals Shares PlungeMid-Afternoon Market Update: Skyline Rises After Q3 Results; EyeGate Pharmaceuticals Shares Plunge
feeds.benzinga.com - April 13 at 3:36 PM
EyeGate Pharma to Post Q2 2018 Earnings of ($0.21) Per Share, Zacks Investment Research Forecasts (EYEG)EyeGate Pharma to Post Q2 2018 Earnings of ($0.21) Per Share, Zacks Investment Research Forecasts (EYEG)
www.americanbankingnews.com - April 13 at 8:47 AM
Eyegate Pharma (EYEG) Announces $11.25 Million Public Offering of Common Stock, WarrantsEyegate Pharma (EYEG) Announces $11.25 Million Public Offering of Common Stock, Warrants
www.streetinsider.com - April 13 at 8:19 AM
EyeGate Pharma prices $11.25M equity offering; shares down 24% premarketEyeGate Pharma prices $11.25M equity offering; shares down 24% premarket
seekingalpha.com - April 13 at 8:19 AM
Eyegate Pharma (EYEG) Secures New Patent for Iontophoretic Contact Lens TechnologyEyegate Pharma (EYEG) Secures New Patent for Iontophoretic Contact Lens Technology
www.streetinsider.com - April 12 at 5:38 PM
Mid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares GainMid-Day Market Update: Analogic Falls Following Acquisition News; EyeGate Pharmaceuticals Shares Gain
www.benzinga.com - April 11 at 5:31 PM
EyeGate nabs U.S. patent covering iontophoretic contact lens; shares up 29%EyeGate nabs U.S. patent covering iontophoretic contact lens; shares up 29%
seekingalpha.com - April 11 at 5:31 PM
EyeGate Issued New Patent for Iontophoretic Contact Lens TechnologyEyeGate Issued New Patent for Iontophoretic Contact Lens Technology
finance.yahoo.com - April 11 at 5:31 PM
Eyegate Pharma (EYEG) Announces FDA Feedback on IDE Amendment for Second Pilot Study of Ocular Bandage GelEyegate Pharma (EYEG) Announces FDA Feedback on IDE Amendment for Second Pilot Study of Ocular Bandage Gel
www.streetinsider.com - April 10 at 8:27 AM
Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo SetbackYour Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback
seekingalpha.com - April 10 at 8:27 AM
EyeGate sees Q3 start for second pilot study of lead candidate EyeGate OBG; shares slip 6% premarketEyeGate sees Q3 start for second pilot study of lead candidate EyeGate OBG; shares slip 6% premarket
seekingalpha.com - April 9 at 5:22 PM
BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation TreatmentBRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment
www.reuters.com - April 6 at 5:41 PM
EyeGate Pharma completes enrollment in late-stage study of EGP-437, milestone earned; shares up 18% premarketEyeGate Pharma completes enrollment in late-stage study of EGP-437, milestone earned; shares up 18% premarket
seekingalpha.com - April 6 at 5:41 PM
Head-To-Head Contrast: EyeGate Pharma (EYEG) versus Regulus Therapeutics (RGLS)Head-To-Head Contrast: EyeGate Pharma (EYEG) versus Regulus Therapeutics (RGLS)
www.americanbankingnews.com - April 2 at 1:16 PM
EyeGate Pharma (EYEG) Given "Buy" Rating at HC WainwrightEyeGate Pharma (EYEG) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - March 31 at 5:28 PM
Eyegate Pharmaceuticals (EYEG) Raised to "Sell" at ValuEngineEyegate Pharmaceuticals (EYEG) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - March 25 at 6:25 PM
BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 MlnBRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln
www.reuters.com - March 23 at 5:42 PM
Eyegate Pharmaceuticals (EYEG) Given a $3.00 Price Target at HC WainwrightEyegate Pharmaceuticals (EYEG) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 18 at 9:22 PM
EyeGate Pharma To Participate At The 30TH Annual ROTH Conference - GlobeNewswire (press release)EyeGate Pharma To Participate At The 30TH Annual ROTH Conference - GlobeNewswire (press release)
globenewswire.com - March 10 at 8:22 AM
EyeGate Pharma To Participate At The 30TH Annual ROTH ConferenceEyeGate Pharma To Participate At The 30TH Annual ROTH Conference
finance.yahoo.com - March 9 at 6:50 PM
EyeGate Pharma Submits Investigational Device Exemption ... - NasdaqEyeGate Pharma Submits Investigational Device Exemption ... - Nasdaq
www.nasdaq.com - March 9 at 8:20 AM

SEC Filings

Eyegate Pharmaceuticals (NASDAQ:EYEG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Eyegate Pharmaceuticals (NASDAQ EYEG) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.